Preference for Infant-Directed Speech in Infants With Hearing Aids: Effects of Early Auditory Experience

Purpose

It is well established that (a) infants prefer listening to infant-directed speech (IDS) over adult-directed speech (ADS), and (b) IDS facilitates speech, language, and cognitive development, compared with ADS. The main purpose of this study was to determine whether infants with hearing aids (HAs), similar to their peers with normal hearing (NH), show a listening preference for IDS over ADS.

Method

A total of 42 infants participated in the study. In Experiment 1, 9 infants with hearing loss, who had approximately 12 months of experience (mean chronological age of 17.57 months) with HAs, and 9 infants with NH, who had similar chronological age (17.54 months), were tested. In Experiment 2, 10 infants with hearing loss, who had approximately 4 months of experience (mean chronological age of 9.86 months) with HAs, and 14 infants with NH, who had similar chronological age (9.09 months), were tested. Infants were tested on their listening preference in 3 randomized blocks: IDS versus silence, ADS versus silence, and IDS versus ADS blocks, using the central fixation preference procedure.

Results

Experiment 1 showed that infants with HAs, similar to their peers with NH, listened longer to both IDS and ADS relative to silence; however, neither infants with HAs nor infants with NH showed a listening preference for IDS over ADS. In Experiment 2, both infants with HAs and infants with NH showed a listening preference for IDS and ADS relative to silence; in addition, both groups preferred listening to IDS over ADS.

Conclusions

Infants with HAs appear to have sufficient access to the acoustic cues in the speech that allow them to develop an age-equivalent IDS preference. This may be attributed to a combination of being able to use the hearing they do have before receiving HAs and early device fitting. Given previously demonstrated positive associations between IDS preference and language development, this research encourages early interventions focusing on maximizing early auditory experience in infants with hearing loss.

Supplemental Material

https://doi.org/10.23641/asha.6906365

from #Audiology via ola Kala on Inoreader https://ift.tt/2OOVAuy
via IFTTT

Intelligent Today, Smarter Tomorrow: Machine Learning in Widex Evoke

Discover how the world's first machine learning algorithm can enhance your hearing aid fittings and end user satisfaction.

from #Audiology via ola Kala on Inoreader https://ift.tt/2LSLxql
via IFTTT

Intelligent Today, Smarter Tomorrow: Machine Learning in Widex Evoke

Discover how the world's first machine learning algorithm can enhance your hearing aid fittings and end user satisfaction.

from #Audiology via ola Kala on Inoreader https://ift.tt/2LSLxql
via IFTTT

FDA Warns against Marketing Hearing Aids as OTC Devices

​The U.S. Food and Drug Administration (FDA) has issued a letter to hearing aid manufacturers warning them not to market hearing aids as over-the-counter devices and reminding them that such a category of product does not exist until the final OTC regulations are published. (http://bit.ly/2OCiMMm.) William Maisel, MD, MPH, stated in the letter that no products that are claimed to address hearing loss are, or can claim to be, OTC hearing aids until that time. "Currently, hearing aids continue to be restricted devices, for which sales must follow applicable federal and state requirements," he wrote. Under section 709 of the FDA Reauthorization Act of 2017 (FDARA), the FDA have until Aug. 18, 2020 to consider public comments and publish the final regulations within 180 days after the close of the comment period. 

Published: 8/3/2018 2:30:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2MhyI5e
via IFTTT

FDA Warns against Marketing Hearing Aids as OTC Devices

​The U.S. Food and Drug Administration (FDA) has issued a letter to hearing aid manufacturers warning them not to market hearing aids as over-the-counter devices and reminding them that such a category of product does not exist until the final OTC regulations are published. (http://bit.ly/2OCiMMm.) William Maisel, MD, MPH, stated in the letter that no products that are claimed to address hearing loss are, or can claim to be, OTC hearing aids until that time. "Currently, hearing aids continue to be restricted devices, for which sales must follow applicable federal and state requirements," he wrote. Under section 709 of the FDA Reauthorization Act of 2017 (FDARA), the FDA have until Aug. 18, 2020 to consider public comments and publish the final regulations within 180 days after the close of the comment period. 

Published: 8/3/2018 2:30:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2MhyI5e
via IFTTT

FDA Warns against Marketing Hearing Aids as OTC Devices

​The U.S. Food and Drug Administration (FDA) has issued a letter to hearing aid manufacturers warning them not to market hearing aids as over-the-counter devices and reminding them that such a category of product does not exist until the final OTC regulations are published. (http://bit.ly/2OCiMMm.) William Maisel, MD, MPH, stated in the letter that no products that are claimed to address hearing loss are, or can claim to be, OTC hearing aids until that time. "Currently, hearing aids continue to be restricted devices, for which sales must follow applicable federal and state requirements," he wrote. Under section 709 of the FDA Reauthorization Act of 2017 (FDARA), the FDA have until Aug. 18, 2020 to consider public comments and publish the final regulations within 180 days after the close of the comment period. 

Published: 8/3/2018 2:30:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2AHwg6O
via IFTTT

FDA Warns against Marketing Hearing Aids as OTC Devices

​The U.S. Food and Drug Administration (FDA) has issued a letter to hearing aid manufacturers warning them not to market hearing aids as over-the-counter devices and reminding them that such a category of product does not exist until the final OTC regulations are published. (http://bit.ly/2OCiMMm.) William Maisel, MD, MPH, stated in the letter that no products that are claimed to address hearing loss are, or can claim to be, OTC hearing aids until that time. "Currently, hearing aids continue to be restricted devices, for which sales must follow applicable federal and state requirements," he wrote. Under section 709 of the FDA Reauthorization Act of 2017 (FDARA), the FDA have until Aug. 18, 2020 to consider public comments and publish the final regulations within 180 days after the close of the comment period. 

Published: 8/3/2018 2:30:00 PM

from #Audiology via ola Kala on Inoreader https://ift.tt/2AHwg6O
via IFTTT